Alphamab Oncology advances cancer treatment innovation. The Hong Kong-listed biopharmaceutical company announced the first patient dosed in Phase I trials for JSKN027, a groundbreaking bispecific antibody-drug conjugate targeting PD-L1 and VEGFR2. This marks a significant milestone as JSKN027 becomes the world's first PD-L1/VEGFR2 bispecific ADC in clinical development. The candidate represents Alphamab's fifth ADC entering trials and addresses critical gaps in solid tumor treatment. By combining immunotherapy, anti-angiogenesis, and targeted chemotherapy mechanisms, JSKN027 targets the synergistic interplay between tumor immune evasion and angiogenesis pathways. The Phase I study will evaluate safety, tolerability, and antitumor activity across multiple centers.
Post from MarketNews_en
Log in to interact with content.